CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Contract Research, Development and Manufacturing Organization

Contract Research, Development and Manufacturing Organization

Transforming Customers Ideas into Impactful Innovation

Syngene is a global, Contract Research, Development and Manufacturing Organization (CRDMO) that partners with leading companies across pharmaceuticals, biotechnology, animal health, consumer goods, and agrochemicals. Syngene provides science across the fully integrated value chain, from biologics and small molecules, early discovery and development to translational and clinical research, and commercial manufacturing.

With cutting-edge infrastructure, a team of over 5,500 scientists, and platforms like SynVent® for integrated drug discovery, we accelerate the journey from concept to clinic. Our unwavering focus on quality, safety, and sustainability ensures that every solution we deliver meets the highest global standards.

Enabling Innovative Scientific Solutions; Transforming Patients' Lives

Syngene’s clients are world leaders in their fields, ranging from leading global multinationals to small and medium-sized start-ups, non-profit institutions, academic institutes and government organizations.

Incorporated in 1993, Syngene is listed separately on the Indian stock exchanges – NSE and BSE. With a unique business model, a talent pool of 5500 scientists, scientific expertise across new therapeutic modalities, an experienced management team, and an independent Board committee, Syngene works for clients around the globe, delivering innovation that benefits human and animal health. As a strategic partner to its clients, often working as an extension of their internal scientific teams, Syngene offers innovative, flexible, and efficient approaches to scale up rapidly. This, in turn, enables faster go-to-market and access to patients.

null

Syngene’s focus on innovation is evident in its approach to integrated, end-to-end services that is spread across drug research, development and manufacturing capabilities covering the entire value chain. Its proprietary platform for integrated services (SynVent) provides an effective and efficient means to advance programs through target validation, translational interrogation, therapeutic discovery, and pre-clinical development for small molecules and biologics.

null

Syngene’s business spans Large Molecules development and manufacturing, Small Molecules Research Services division supports the full spectrum of early-stage R&D, from target identification to clinical transition and commercial manufacturing. and Dedicated R&D Centers.

Syngene is a fully integrated organization offering end-to-end scientific solutions across research, development, and commercial manufacturing. With expertise in both small and large molecules, we serve global pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries. Our strong track record in customer satisfaction, scientific innovation and operational excellence has made us a trusted partner for multinational corporations, emerging biotech firms, academic institutions, non-profit organizations, and government agencies. We offer flexible, customized partnership models, spanning from specialist services to long-term strategic programs. Beyond business performance, we remain committed to sustainability and responsible corporate citizenship. Our ESG initiatives focus on reducing our carbon footprint, ensuring workplace safety, and making a positive impact in the communities where we operate.

Exceptional Partnerships
Dynamic Growth

The dictionary definition of ‘partnership’ describes a contractual relationship. However, when applied in context, the concept expresses something more: a common interest, a shared commitment, complementary skills and a desire to work together. These are the characteristics of the relationships that we aim to build. Our experience suggests that strong processes, regular communication, transparency, exchanges of ideas – even disappointments – help to increase our understanding of our clients’ values and ambitions, while building trust between our teams. The more we understand, the more we can plan and shape projects that deliver results: sometimes beyond expectations, always high-quality science.

Read More >>

Syngene Annual Report 2025: Innovating Reach

Syngene’s culture is driven by the expertise of more than 8,200 employees and workers, including over 5,600 scientists. Our headquarters and main campus, serving as the central hub for research, development, and manufacturing, are located in Bengaluru, India. Large-molecule development and manufacturing take place at our main campus, complemented by a newly operational multi modal biologics manufacturing unit (Unit 3). In addition, we operate three satellite campuses in Bengaluru that support key corporate functions, including Human Resources, Legal, and Finance, alongside our Clinical Development facility. To meet the growing demands of our research operations, we have expanded to Hyderabad, while our Mangaluru facility specializes in the commercial-scale production of active pharmaceutical ingredients (APIs). The acquisition of a biologics manufacturing facility in Baltimore, Maryland, United States, further strengthening our presence in large molecule development and production.

KMS
OUR LEGACY
SHAREHOLDER SERVICES
 LEARNING & DEVELOPMENT
SUSTAINABILITY
KEY THERAPEUTIC AREAS
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>